The endotoxin-detecting reagents that Seikagaku provides are mainly used in quality control of pharmaceutical and medical device manufacturing processes and water quality control of dialysate used in artificial dialysis.

Seikagaku is engaged in the development of the LAL business in Japan, selling endotoxin-detecting reagents and related devices mainly to pharmaceutical companies that manufacture injectable formulations, while wholly owned subsidiary Associates of Cape Cod, Inc. (ACC) handles overseas business development. ACC is the first company in the world to successfully develop endotoxindetecting reagents from limulus amebocyte lysate (LAL), and it obtained U.S. Food and Drug Administration (FDA) approval in 1977. ACC plays an important role in the overseas business expansion through its global sales network, mainly in the U.S. and Europe, through the manufacturing and sales of endotoxin-detecting reagents, as well as beta-glucan-detecting in vitro reagent to diagnose invasive fungal disease.

Related Information